OpGen (OPGN) to Release Earnings on Thursday

OpGen (NASDAQ:OPGN) will release its earnings data on Thursday, April 4th.

OpGen Trading Up 3.1 %

Shares of OPGN traded up $0.02 during mid-day trading on Wednesday, hitting $0.64. The company’s stock had a trading volume of 478,141 shares, compared to its average volume of 1,630,271. The firm has a 50-day simple moving average of $0.47 and a 200 day simple moving average of $0.47. The firm has a market capitalization of $6.41 million, a P/E ratio of -0.09 and a beta of -0.71. OpGen has a 1-year low of $0.17 and a 1-year high of $3.84.

Analyst Ratings Changes

Separately, StockNews.com began coverage on OpGen in a research note on Friday, March 29th. They issued a “sell” rating for the company.

Hedge Funds Weigh In On OpGen

Several hedge funds have recently bought and sold shares of OPGN. HRT Financial LP purchased a new position in OpGen in the 4th quarter valued at approximately $26,000. Citadel Advisors LLC increased its position in OpGen by 571.0% during the third quarter. Citadel Advisors LLC now owns 100,773 shares of the medical research company’s stock worth $29,000 after buying an additional 85,754 shares in the last quarter. Dimensional Fund Advisors LP purchased a new position in OpGen during the first quarter worth $49,000. Finally, Vanguard Group Inc. increased its position in OpGen by 39.8% during the third quarter. Vanguard Group Inc. now owns 1,877,597 shares of the medical research company’s stock worth $537,000 after buying an additional 534,960 shares in the last quarter. 2.68% of the stock is owned by hedge funds and other institutional investors.

OpGen Company Profile

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.